{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:01:57Z","timestamp":1790056917998,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2006,1]]},"DOI":"10.1016\/j.canlet.2005.02.005","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T21:24:01Z","timestamp":1111094641000},"page":"247-256","source":"Crossref","is-referenced-by-count":45,"title":["The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling"],"prefix":"10.1016","volume":"231","author":[{"given":"\u00d6zcan","family":"Met","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders E.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens H.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Buus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens H.","family":"Claesson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2005.02.005_bib1","first-page":"2444","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.02.005_bib2","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.4049\/jimmunol.168.5.2393","article-title":"Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity","volume":"168","author":"Shibagaki","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib3","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","article-title":"Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte\/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib4","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.194.4.481","article-title":"Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy","volume":"194","author":"van Elsas","year":"2001","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00002371-200211000-00002","article-title":"CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells","volume":"25","author":"Hsu","year":"2002","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2005.02.005_bib6","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/S0264-410X(00)00061-X","article-title":"Augmentation of antitumor immunity by genetically engineered fibroblast cells to express both B7.1 and interleukin-7","volume":"18","author":"Kim","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.canlet.2005.02.005_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4049\/jimmunol.150.4.1212","article-title":"Primary in vivo responses to ovalbumin. Probing the predictive value of the Kb binding motif","volume":"150","author":"Lipford","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib8","doi-asserted-by":"crossref","first-page":"S259","DOI":"10.1016\/S0360-3016(03)01097-6","article-title":"Combination of local radiation with CTLA4 blockade: a new approach to the immunotherapy of breast cancer","volume":"57","author":"Demaria","year":"2003","journal-title":"Int. J. Radiat Oncol. Biol. Phys."},{"key":"10.1016\/j.canlet.2005.02.005_bib9","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0092-8674(88)91043-4","article-title":"Introduction of soluble protein into the class I pathway of antigen processing and presentation","volume":"54","author":"Moore","year":"1988","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2005.02.005_bib10","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1084\/jem.153.5.1198","article-title":"Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition","volume":"153","author":"Kappler","year":"1981","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib11","doi-asserted-by":"crossref","first-page":"804","DOI":"10.4049\/jimmunol.145.3.804","article-title":"Generation of class I MHC-restricted T-T hybridomas","volume":"145","author":"Rock","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib12","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/S0008-8749(03)00128-X","article-title":"Peptide-loaded dendritic cells prime and activate MHC-class I-restricted T cells more efficiently than protein-loaded cross-presenting DC","volume":"222","author":"Met","year":"2003","journal-title":"Cell Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib14","doi-asserted-by":"crossref","first-page":"15420","DOI":"10.1016\/S0021-9258(18)98632-1","article-title":"Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity","volume":"266","author":"Lalani","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2005.02.005_bib15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0165-2478(03)00158-5","article-title":"Comparison of CTL reactivity in the spleen and draining lymph nodes after immunization with peptides pulsed on dendritic cells or mixed with Freund's incomplete adjuvant","volume":"90","author":"Wang","year":"2003","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.canlet.2005.02.005_bib16","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1046\/j.1365-3083.2003.01313.x","article-title":"Immunobiological effects of glucosamine in vitro","volume":"58","author":"Forchhammer","year":"2003","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib17","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1046\/j.1365-2362.2003.01194.x","article-title":"Immature dendritic cell\/tumor cell fusions induce potent antitumour immunity","volume":"33","author":"Takeda","year":"2003","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.canlet.2005.02.005_bib18","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nm0597-558","article-title":"Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells","volume":"3","author":"Gong","year":"1997","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib19","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1046\/j.1365-2567.1999.00823.x","article-title":"Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells","volume":"97","author":"Cao","year":"1999","journal-title":"Immunology"},{"key":"10.1016\/j.canlet.2005.02.005_bib20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1006\/clim.2001.5112","article-title":"Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice","volume":"101","author":"Tanaka","year":"2001","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/73193","article-title":"Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids","volume":"6","author":"Kugler","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib22","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib23","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1054\/bjoc.2001.1801","article-title":"Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens","volume":"84","author":"Okada","year":"2001","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2005.02.005_bib24","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.4049\/jimmunol.156.8.2918","article-title":"Induction of antitumor immunity using bone marrow-generated dendritic cells","volume":"156","author":"Porgador","year":"1996","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib25","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3295::AID-IMMU3295>3.0.CO;2-N","article-title":"MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope","volume":"29","author":"el Shami","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib26","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canlet.2005.02.005_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv. Immunol."},{"key":"10.1016\/j.canlet.2005.02.005_bib28","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0167-5699(95)80033-6","article-title":"Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance","volume":"16","author":"Ferrone","year":"1995","journal-title":"Immunol. Today"},{"key":"10.1016\/j.canlet.2005.02.005_bib29","first-page":"4679","article-title":"Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin","volume":"44","author":"Natali","year":"1984","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2005.02.005_bib30","first-page":"175","article-title":"Lack of expression of HLA-ABC antigens in choriocarcinoma and other human tumor cell lines","volume":"60","author":"Travers","year":"1982","journal-title":"Natl Cancer Inst. Monogr."},{"key":"10.1016\/j.canlet.2005.02.005_bib31","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1084\/jem.188.2.409","article-title":"Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction","volume":"188","author":"Kurts","year":"1998","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2005.02.005_bib32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/ni0702-611","article-title":"CTLA-4: new insights into its biological function and use in tumor immunotherapy","volume":"3","author":"Egen","year":"2002","journal-title":"Nat. Immunol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383505000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383505000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T17:17:01Z","timestamp":1683047821000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383505000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,1]]}},"alternative-id":["S0304383505000972"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2005.02.005","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2006,1]]}}}